Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy
JIANG H, WANG H, WANG S, PEI Z, FU Z, FANG C, WANG J, LU Q, WANG E, LI J. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy. Molecular Medicine Reports 2014, 11: 3523-3532. PMID: 25573098, DOI: 10.3892/mmr.2014.3141.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDNA-Binding ProteinsDrug Resistance, NeoplasmEndonucleasesFemaleGene ExpressionHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMyoD ProteinMyoglobinMyosin Type IIPlatinumPleural Effusion, MalignantPrognosisRibonucleoside Diphosphate ReductaseThymidylate SynthaseTubulinTumor Suppressor ProteinsConceptsExcision repair cross-complementing gene 1Expression of ERCC1Platinum-based chemotherapyMetastatic lung adenocarcinomaLung adenocarcinomaPleural effusionLung Adenocarcinoma Pleural EffusionsPlatinum-based chemotherapy treatmentTumor cellsUntreated lung adenocarcinomasSurvival of patientsMalignant pleural effusionPleural fluid samplesExpression levelsProtein expression levelsWestern blot analysisClinical outcomesPatient survivalLung cancerChemotherapy treatmentLung carcinomaNon-muscle myosin IIPatientsAdenocarcinomaSurvival rate